Back to results
US 2026/0167605 A1Published application
Crystalline 5-methoxy-n,n-diallyltryptamine compounds
AssigneeCaamtech, Inc.
InventorAndrew R. CHADEAYNE
Life of this patent
Estimating the term…
Abstract
The disclosure relates to 5-methoxy-N,N-diallyltryptamine (“5-MeO-DALT”), bis-(5-meth-oxy-N,N-di-allyl-tryptammonium) fumarate (“5-MeO-DALT fumarate”), and crystalline bis-(5-meth-oxy-N,N-di-allyl-tryptammonium) fumarate (“5-MeO-DALT fumarate”), compositions containing them, and the methods of treatment using them.
Claims8
1-20. (canceled)
A method of preventing or treating a brain disorder, the method comprising the step of:
- administering to a subject in need thereof a therapeutically effective amount of bis-(5-meth-oxy-N,N-di-allyl-tryptammonium) fumarate (5-MeO-DALT fumarate).
A method of preventing or treating a disorder selected from the group consisting of:
- a developmental disorder;
- delirium;
- an amnestic disorder;
- a cognitive disorder;
- a psychiatric disorder due to a somatic condition;
- a drug-related disorder;
- a mood disorder;
- an anxiety disorder;
- a somatoform disorder;
- a factitious disorder;
- a dissociative disorder;
- an eating disorder;
- a sleep disorder;
- an impulse control disorder;
- an adjustment disorder;
- and a personality disorder, the method comprising the step of:
- administering to a subject in need thereof a therapeutically effective amount of bis-(5-meth-oxy-N,N-di-allyl-tryptammonium) fumarate (5-MeO-DALT fumarate).
14 more elements
Dependencies are inferred from the claim text.